Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03754933 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
A Phase 1 study, sponsored by GeoVax.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03754933 is a Phase 1 study that has completed, run by GeoVax. The registered enrollment target is 10 participants.
The verdict
NCT03754933, a Phase 1 study, has completed, sponsored by GeoVax.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with advanced head and neck cancer in a completed phase I study. Secondary Objective: The secondary objective is to evaluate the antitumor activity of repeat administration of Ad/PNP plus F-araAMP. FDA Office of Orphan Drugs Division is a source of funding for the overall project.
Interventions
- DRUG Fludarabine Phosphate
- BIOLOGICAL Ad/PNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03754933
The ClinicalTrials.gov registry entry for NCT03754933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GeoVax, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fludarabine Phosphate is the first listed.
NCT03754933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03754933 about?
NCT03754933 is a clinical study titled "Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer". Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with advanced head and neck cancer in a completed phase I study. Secondary Obje...
What is the current status of trial NCT03754933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-02-11. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT03754933?
The interventions under investigation include: Fludarabine Phosphate (DRUG), Ad/PNP (BIOLOGICAL).
Who is sponsoring clinical trial NCT03754933?
This trial is sponsored by GeoVax, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.